Frontline Treatment Considerations in Endometrial Cancer

Panelists discuss how the introduction of pembrolizumab plus chemotherapy has expanded the landscape of frontline immunotherapy options for advanced or recurrent endometrial cancer. They compare this regimen with other checkpoint inhibitor combinations, focusing on key considerations for selecting the most appropriate therapy. Factors such as tumor biomarkers, previous treatment exposure, and patient-specific tolerability play a vital role in guiding clinical decisions.

The discussion emphasizes the role of established treatment guidelines, including NCCN recommendations, which provide evidence-based frameworks to navigate complex therapeutic choices. Panelists highlight that while multiple immunotherapy-based options are now available, optimal use depends on understanding differences in mechanism, toxicity, and long-term benefit.

In conclusion, the panel reflects on how these evolving standards of care represent a new era in endometrial cancer treatment. They advocate for continued data integration, clinician education, and guideline alignment to ensure consistent and effective application of immunotherapy in the frontline setting.